BioSim™ anti-HER2 Mab (Human) ELISA Kit

Anti-HER2 is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). It has antitumor activity against HER2-positive human breast tumor cells in laboratory models and is active for the treatment of women with HER2-overexpressing breast cancers. In HER2 overexpressing cells, this antibody markedly down-regulates HER2 expression by accelerating receptor endocytosis and degradation and inhibits cell cycle progression by inducing the formation of p27Kip1/Cdk2 complexes. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-HER2 ELISA kit is designed to quantify/measure the antibody against anti-HER2 monoclonal antibody with high specificity and sensitivity in biological matrices. The kit is based on the Sandwich principle. Standards and samples (serum or plasma) are added to the microtiter plate coated with anti-HER2 monoclonal antibody. After incubation, the wells are washed. The HRP conjugated probe is added and binds to the antibodies against anti-HER2 that is captured by monoclonal antibody coated on the wells. Following incubation, wells are washed and the enzymatic activity is detected by the addition of TMB chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies against anti-HER2 in the sample or standard. The quantitative test results can be evaluated using the standard curve.